SAN DIEGO (September 13, 2018)—ResMed introduced its first minimal-contact full-face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps users reduce facial marks, wear glasses in bed and curl up closer to their bed partner.
AirFit F30 sits below the nasal bridge, preventing top-of-the-nose red marks and irritation, and reducing feelings of claustrophobia for some full-face wearers.
SAN DIEGO (August 27, 2018)—ResMed, a provider of in cloud-connected respiratory care devices, announced upgrades to its Astral life support ventilators, including optional AutoEPAP in iVAPS for U.S. patients, a high-demand therapy option.
What is AutoEPAP?
SAN DIEGO and SAN FRANCISCO (July 11, 2018)—ResMed a provider of sleep apnea treatment and connected health solutions, and Verily, an Alphabet company, announced their agreement to form a new joint venture.
SAN DIEGO (May 29, 2018)—ResMed a provider of connected health care solutions, announced it has entered into a definitive agreement to acquire privately held HEALTHCAREfirst, a provider of software solutions and services for home health and hospice agencies.
SAN DIEGO (May 21, 2018)—New data analysis presented by ResMed this week at the American Thoracic Society's 2018 International Conference indicates that the prevalence of sleep apnea impacts more than 936 million people worldwide—nearly 10 times greater than previous estimates.
NEW YORK (April 24, 2018)—The ATS Foundation announced its new ATS Foundation/ResMed Research Fellowship in Sleep-disordered Breathing and PAP Therapy.
The award will provide funding for two years in the amount of $100,000, provided by ResMed, a global provider of connected health with more than 4 million cloud-connected PAP devices monitoring patients every night.
SAN DIEGO (April 2, 2018)—ResMed announced the hire of its first chief technology officer (CTO), Bobby Ghoshal.
As CTO, Ghoshal will lead ResMed’s global health care informatics and data analytics team to drive its cloud-based digital health platforms, as well as investments in emerging health technologies such as artificial intelligence and machine learning.
NEW YORK (February 12, 2018)—Jeremy Orr, MD, of University of California, San Diego, has been awarded the new ATS Foundation/ResMed Research Fellowship in Noninvasive Ventilation (NIV) in COPD.
ResMed is a provider of NIV devices for treating COPD (chronic obstructive pulmonary disease) in the home and hospital.
Dr. Orr’s $100,000 award will support his research focused on the impact of noninvasive ventilation on cardiovascular biomarkers in COPD.
SAN DIEGO (January 25, 2018)—Switching from positive airway pressure (PAP) to adaptive servo ventilation (ASV) therapy can help patients with central sleep apnea be more adherent on therapy, according to a ResMed-funded study published in the Journal of Clinical Sleep Medicine (JCSM).
The study analyzed anonymous, aggregated data from the devices of 198,890 telemonitored U.S. patients with treatment-emergent central sleep apnea who started on PAP therapy, and found that:
SAN FRANCISCO (January 8, 2018)—ResMed today introduced Mobi, its first ResMed-branded portable oxygen concentrator (POC).
Mobi offers a balance of oxygen delivery, weight and battery life so that millions with chronic obstructive pulmonary disease (COPD) or other respiratory condition can enjoy ResMed-quality oxygen therapy at home or on the go.
SAN DIEGO (December 12, 2017)—ResMed today was named one of America’s top 100 corporate citizens for the second straight year by Forbes and JUST Capital, a nonprofit that analyzes and ranks companies based on how they serve the priorities of the American people.
ResMed ranked #76 among other large publicly traded U.S. companies and #2 in “Health Care Equipment & Services” when compared on issues including:
SAN DIEGO (December 6, 2017)—ResMed has been named a 2017 “Medtech Company of the Year” finalist by MD+DI, a news resource in the medical device and diagnostic industry.
SAN DIEGO (November 21, 2017)—CHEST, the publication of the American College of Chest Physicians, has published a ResMed study that shows patient engagement apps significantly improve adherence to positive airway pressure (PAP) therapy.
The research included more than 128,000 patients, making it the world's largest study to look at sleep apnea and self-monitoring.
ATLANTA (October 23, 2017)—Eight finalists in the 2017 Innovative HME Retail Product Awards, sponsored by HomeCare Magazine, took 3.5 minutes each on day one of Medtrade to state their case as to why their product was the best to boost cash sales.
Eight Finalists
ATLANTA (September 12, 2017)—Managing compliance for sleep apnea patients and increasing resupply revenue just got easier for home medical equipment (HME) providers, as Brightree today announced automated resupply enrollment for patients managed by both Brightree and AirView by ResMed.
ATLANTA (July 5, 2017)—Brightree LLC, a provider of cloud-based software to improve business and clinical performance of post-acute care organizations, announced today that it has acquired AllCall Connect, a provider of a live-calling solution for CPAP (continuous positive airway pressure) patient resupply.
SAN DIEGO, Calif. (April 25, 2017)—ResMed today unveiled its AirMini, the world’s smallest CPAP machine.
AirMini packs ResMed’s clinically proven CPAP (continuous positive airway pressure) technology along with its comfort and ease-of-use features into a sleek, portable, pocket-sized device ideal for traveling. The AirMini is available with ResMed’s proprietary AutoSet functionality as well as an innovative, built-in humidification system for patient comfort.
MARSEILLES, France and SAN DIEGO (April 6, 2017)—ResMed Inc. today announced that people with obstructive sleep apnea who develop central sleep apnea (CSA) are more compliant on therapy after they switch from continuous positive airway pressure (CPAP) therapy to adaptive servo-ventilation (ASV) therapy, according to the largest-ever analysis of patients with treatment-emergent CSA.
